Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Ndel1 oligopeptidase activity as a potential biomarker of early stages of schizophrenia.

Dal Mas C, Nani JV, Noto C, Yonamine CM, da Cunha GR, Mansur RB, Ota VK, Belangero SI, Cordeiro Q, Kapczinski F, Brietzke E, Bressan RA, Gadelha A, Hayashi MAF.

Schizophr Res. 2019 Mar 8. pii: S0920-9964(19)30081-7. doi: 10.1016/j.schres.2019.02.021. [Epub ahead of print]

PMID:
30857875
2.

Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis.

Noto MN, Maes M, Nunes SOV, Ota VK, Rossaneis AC, Verri WA Jr, Cordeiro Q, Belangero SI, Gadelha A, Bressan RA, Noto C.

Eur Neuropsychopharmacol. 2019 Mar;29(3):416-431. doi: 10.1016/j.euroneuro.2018.12.008. Epub 2018 Dec 26.

PMID:
30594344
3.

Cannabis acute use impacts symptoms and functionality in a cohort of antipsychotic naïve First Episode of Psychosis individuals.

Coutinho LS, Honorato H, Higuchi CH, Cavalcante DA, Belangeiro S, Noto M, Bressan RA, Cordeiro Q, Noto C, Gadelha A.

Schizophr Res Cogn. 2018 Dec 11;16:12-16. doi: 10.1016/j.scog.2018.10.002. eCollection 2019 Jun.

4.

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder.

de Jong S, Diniz MJA, Saloma A, Gadelha A, Santoro ML, Ota VK, Noto C; Major Depressive Disorder and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium, Curtis C, Newhouse SJ, Patel H, Hall LS, O Reilly PF, Belangero SI, Bressan RA, Breen G.

Commun Biol. 2018 Oct 8;1:163. doi: 10.1038/s42003-018-0155-y. eCollection 2018.

5.

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.

Santoro ML, Ota V, de Jong S, Noto C, Spindola LM, Talarico F, Gouvea E, Lee SH, Moretti P, Curtis C, Patel H, Newhouse S, Carvalho CM, Gadelha A, Cordeiro Q, Bressan RA, Belangero SI, Breen G.

Transl Psychiatry. 2018 Aug 31;8(1):174. doi: 10.1038/s41398-018-0230-7.

6.

An unusual association of hadrosaur and therizinosaur tracks within Late Cretaceous rocks of Denali National Park, Alaska.

Fiorillo AR, McCarthy PJ, Kobayashi Y, Tomsich CS, Tykoski RS, Lee YN, Tanaka T, Noto CR.

Sci Rep. 2018 Aug 3;8(1):11706. doi: 10.1038/s41598-018-30110-8.

7.

Investigating brain structural patterns in first episode psychosis and schizophrenia using MRI and a machine learning approach.

de Moura AM, Pinaya WHL, Gadelha A, Zugman A, Noto C, Cordeiro Q, Belangero SI, Jackowski AP, Bressan RA, Sato JR.

Psychiatry Res Neuroimaging. 2018 May 30;275:14-20. doi: 10.1016/j.pscychresns.2018.03.003. Epub 2018 Mar 6.

PMID:
29548527
8.

Accessing Gene Expression in Treatment-Resistant Schizophrenia.

Moretti PN, Ota VK, Gouvea ES, Pedrini M, Santoro ML, Talarico F, Spindola LM, Carvalho CM, Noto C, Xavier G, Brietzke E, Gadelha A, Bressan R, Mari J, Belangero S.

Mol Neurobiol. 2018 Aug;55(8):7000-7008. doi: 10.1007/s12035-018-0876-4. Epub 2018 Jan 26.

PMID:
29374346
9.

Leukocyte telomere length variation in different stages of schizophrenia.

Maurya PK, Rizzo LB, Xavier G, Tempaku PF, Ota VK, Santoro ML, Spíndola LM, Moretti PS, Mazzotti DR, Gadelha A, Gouvea ES, Noto C, Maes M, Cordeiro Q, Bressan RA, Brietzke E, Belangero SI.

J Psychiatr Res. 2018 Jan;96:218-223. doi: 10.1016/j.jpsychires.2017.10.016. Epub 2017 Oct 21.

PMID:
29102816
10.

New data towards the development of a comprehensive taphonomic framework for the Late Jurassic Cleveland-Lloyd Dinosaur Quarry, Central Utah.

Peterson JE, Warnock JP, Eberhart SL, Clawson SR, Noto CR.

PeerJ. 2017 Jun 6;5:e3368. doi: 10.7717/peerj.3368. eCollection 2017.

11.

Oxidative and nitrosative stress biomarkers in chronic schizophrenia.

Boll KM, Noto C, Bonifácio KL, Bortolasci CC, Gadelha A, Bressan RA, Barbosa DS, Maes M, Moreira EG.

Psychiatry Res. 2017 Jul;253:43-48. doi: 10.1016/j.psychres.2017.03.038. Epub 2017 Mar 21.

PMID:
28346888
12.

Shorter leukocyte telomere length in patients at ultra high risk for psychosis.

Maurya PK, Rizzo LB, Xavier G, Tempaku PF, Zeni-Graiff M, Santoro ML, Mazzotti DR, Zugman A, Pan P, Noto C, Maes M, Asevedo E, Mansur RB, Cunha GR, Gadelha A, Bressan RA, Belangero SI, Brietzke E.

Eur Neuropsychopharmacol. 2017 May;27(5):538-542. doi: 10.1016/j.euroneuro.2017.02.008. Epub 2017 Mar 6.

PMID:
28274506
13.

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls.

Matsuzaka CT, Christofolini D, Ota VK, Gadelha A, Berberian AA, Noto C, Mazzotti DR, Spindola LM, Moretti PN, Smith MAC, Melaragno MI, Belangero SI, Bressan RA.

Braz J Psychiatry. 2017 Oct-Dec;39(4):302-308. doi: 10.1590/1516-4446-2016-1987. Epub 2017 Mar 2.

14.

Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway.

Kanchanatawan B, Sirivichayakul S, Thika S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Noto C, Ivanova R, Maes M.

Metab Brain Dis. 2017 Aug;32(4):1003-1016. doi: 10.1007/s11011-017-9982-7. Epub 2017 Mar 3.

PMID:
28258445
15.

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia.

Pinaya WH, Gadelha A, Doyle OM, Noto C, Zugman A, Cordeiro Q, Jackowski AP, Bressan RA, Sato JR.

Sci Rep. 2016 Dec 12;6:38897. doi: 10.1038/srep38897.

16.

New evidence in support of staging approaches in schizophrenia: Differences in clinical profiles between first episode, early stage, and late stage.

Ortiz BB, Eden FD, de Souza AS, Teciano CA, de Lima DM, Noto C, Higuchi CH, Cogo-Moreira H, Bressan RA, Gadelha A.

Compr Psychiatry. 2017 Feb;73:93-96. doi: 10.1016/j.comppsych.2016.11.006. Epub 2016 Nov 18.

PMID:
27923116
17.

Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis.

Gouvea ES, Ota VK, Noto C, Santoro ML, Spindola LM, Moretti PN, Carvalho CM, Xavier G, Rios AC, Sato JR, Hayashi MA, Brietzke E, Gadelha A, Bressan RA, Cordeiro Q, Belangero SI.

Transl Psychiatry. 2016 Oct 4;6(10):e908. doi: 10.1038/tp.2016.159.

18.

Risk stratification, perioperative and periprocedural management of the patient receiving anticoagulant therapy.

Oprea AD, Noto CJ, Halaszynski TM.

J Clin Anesth. 2016 Nov;34:586-99. doi: 10.1016/j.jclinane.2016.06.016. Epub 2016 Jul 18. Review.

PMID:
27687455
19.

Hair cortisol in drug-naïve first-episode individuals with psychosis.

Andrade EH, Rizzo LB, Noto C, Ota VK, Gadelha A, Daruy-Filho L, Tasso Bde C, Mansur RB, Cordeiro Q, Belangero SI, Bressan RA, Grassi-Oliveira R, Brietzke E.

Braz J Psychiatry. 2016 Mar;38(1):11-6. doi: 10.1590/1516-4446-2014-1634. Epub 2016 Jan 26.

20.

Clinical characteristics and influence of childhood trauma on the prodrome of bipolar disorder.

Noto MN, Noto C, Caribé AC, Miranda-Scippa Â, Nunes SO, Chaves AC, Amino D, Grassi-Oliveira R, Correll CU, Brietzke E.

Braz J Psychiatry. 2015 Oct-Dec;37(4):280-8. doi: 10.1590/1516-4446-2014-1641.

21.

Depression, Cytokine, and Cytokine by Treatment Interactions Modulate Gene Expression in Antipsychotic Naïve First Episode Psychosis.

Noto C, Ota VK, Santoro ML, Gouvea ES, Silva PN, Spindola LM, Cordeiro Q, Bressan RA, Gadelha A, Brietzke E, Belangero SI, Maes M.

Mol Neurobiol. 2016 Oct;53(8):5701-9. doi: 10.1007/s12035-015-9489-3. Epub 2015 Oct 22.

PMID:
26491028
22.

Increased expression of NDEL1 and MBP genes in the peripheral blood of antipsychotic-naïve patients with first-episode psychosis.

Ota VK, Noto C, Santoro ML, Spindola LM, Gouvea ES, Carvalho CM, Santos CM, Xavier G, Higuchi CH, Yonamine C, Moretti PN, Abílio VC, Hayashi MA, Brietzke E, Gadelha A, Cordeiro Q, Bressan RA, Belangero SI.

Eur Neuropsychopharmacol. 2015 Dec;25(12):2416-25. doi: 10.1016/j.euroneuro.2015.09.013. Epub 2015 Oct 9.

PMID:
26476704
23.

Structural covariance in schizophrenia and first-episode psychosis: An approach based on graph analysis.

Zugman A, Assunção I, Vieira G, Gadelha A, White TP, Oliveira PP, Noto C, Crossley N, Mcguire P, Cordeiro Q, Belangero SI, Bressan RA, Jackowski AP, Sato JR.

J Psychiatr Res. 2015 Dec;71:89-96. doi: 10.1016/j.jpsychires.2015.09.018. Epub 2015 Oct 22.

PMID:
26458012
24.

The role of oxidative and nitrosative stress in accelerated aging and major depressive disorder.

Maurya PK, Noto C, Rizzo LB, Rios AC, Nunes SO, Barbosa DS, Sethi S, Zeni M, Mansur RB, Maes M, Brietzke E.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:134-44. doi: 10.1016/j.pnpbp.2015.08.016. Epub 2015 Sep 6. Review.

PMID:
26348786
25.

Serum brain-derived neurotrophic factor and cortical thickness are differently related in patients with schizophrenia and controls.

Zugman A, Pedrini M, Gadelha A, Kempton MJ, Noto CS, Mansur RB, Santoro ML, Gama CS, Bressan RA, McGuire P, Jackowski AP, Brietzke E.

Psychiatry Res. 2015 Oct 30;234(1):84-9. doi: 10.1016/j.pscychresns.2015.08.009. Epub 2015 Aug 28.

PMID:
26341949
26.

Angiotensin converting enzyme activity is positively associated with IL-17a levels in patients with schizophrenia.

Gadelha A, Yonamine CM, Nering M, Rizzo LB, Noto C, Cogo-Moreira H, Teixeira AL, Bressan R, Maes M, Brietzke E, Hayashi MA.

Psychiatry Res. 2015 Oct 30;229(3):702-7. doi: 10.1016/j.psychres.2015.08.018. Epub 2015 Aug 12.

PMID:
26296754
27.

Oxidative stress in drug naïve first episode psychosis and antioxidant effects of risperidone.

Noto C, Ota VK, Gadelha A, Noto MN, Barbosa DS, Bonifácio KL, Nunes SO, Cordeiro Q, Belangero SI, Bressan RA, Maes M, Brietzke E.

J Psychiatr Res. 2015 Sep;68:210-6. doi: 10.1016/j.jpsychires.2015.07.003. Epub 2015 Jul 3.

PMID:
26228421
28.

High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance.

Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E.

World J Biol Psychiatry. 2015 Sep;16(6):422-429. doi: 10.3109/15622975.2015.1062552. Epub 2015 Jul 27.

PMID:
26212792
29.

Lowered paraoxonase 1 (PON1) activity is associated with increased cytokine levels in drug naïve first episode psychosis.

Brinholi FF, Noto C, Maes M, Bonifácio KL, Brietzke E, Ota VK, Gadelha A, Cordeiro Q, Belangero SI, Bressan RA, Vargas HO, Higachi L, de Farias CC, Moreira EG, Barbosa DS.

Schizophr Res. 2015 Aug;166(1-3):225-30. doi: 10.1016/j.schres.2015.06.009. Epub 2015 Jun 27.

PMID:
26123170
30.

Gene expression analysis in blood of ultra-high risk subjects compared to first-episode of psychosis patients and controls.

Santoro ML, Gadelha A, Ota VK, Cunha GR, Asevedo E, Noto CS, Spindola LM, Pan PM, Talarico F, Mansur RB, Silva PN, Brietzke E, Cordeiro Q, Bressan RA, Belangero SI.

World J Biol Psychiatry. 2015 Sep;16(6):441-446. doi: 10.3109/15622975.2015.1048724. Epub 2015 Jun 18.

PMID:
26089098
31.

Determinants of adherence to treatment in first-episode psychosis: a comprehensive review.

Leclerc E, Noto C, Bressan RA, Brietzke E.

Braz J Psychiatry. 2015 Apr-Jun;37(2):168-76. doi: 10.1590/1516-4446-2014-1539. Epub 2015 May 1. Review.

32.

Toward Omics-Based, Systems Biomedicine, and Path and Drug Discovery Methodologies for Depression-Inflammation Research.

Maes M, Nowak G, Caso JR, Leza JC, Song C, Kubera M, Klein H, Galecki P, Noto C, Glaab E, Balling R, Berk M.

Mol Neurobiol. 2016 Jul;53(5):2927-2935. doi: 10.1007/s12035-015-9183-5. Epub 2015 May 2. Review.

PMID:
25934103
33.

Omics-based depression and inflammation research.

Maes M, Noto C, Brietzke E.

Braz J Psychiatry. 2015 Jan-Mar;37(1):1-2. doi: 10.1590/1516-4446-2015-3609. No abstract available.

34.

Effects of depression on the cytokine profile in drug naïve first-episode psychosis.

Noto C, Ota VK, Santoro ML, Ortiz BB, Rizzo LB, Higuchi CH, Cordeiro Q, Belangero SI, Bressan RA, Gadelha A, Maes M, Brietzke E.

Schizophr Res. 2015 May;164(1-3):53-8. doi: 10.1016/j.schres.2015.01.026. Epub 2015 Feb 21.

PMID:
25716958
35.

Disorganized Symptoms Predicted Worse Functioning Outcome in Schizophrenia Patients with Established Illness.

Ortiz BB, Gadelha A, Higuchi CH, Noto C, Medeiros D, Pitta JCDN, de Araújo Filho GM, Hallak JEC, Bressan RA.

Clin Schizophr Relat Psychoses. Fall 2017;11(3):151-155. doi: 10.3371/CSRP.ORGA.022015. Epub 2015 Feb 24.

PMID:
25711508
36.

Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis.

Noto C, Ota VK, Gouvea ES, Rizzo LB, Spindola LM, Honda PH, Cordeiro Q, Belangero SI, Bressan RA, Gadelha A, Maes M, Brietzke E.

Int J Neuropsychopharmacol. 2014 Oct 31;18(4). pii: pyu042. doi: 10.1093/ijnp/pyu042.

37.

Changes in gene expression and methylation in the blood of patients with first-episode psychosis.

Ota VK, Noto C, Gadelha A, Santoro ML, Spindola LM, Gouvea ES, Stilhano RS, Ortiz BB, Silva PN, Sato JR, Han SW, Cordeiro Q, Bressan RA, Belangero SI.

Schizophr Res. 2014 Nov;159(2-3):358-64. doi: 10.1016/j.schres.2014.09.008. Epub 2014 Sep 28.

PMID:
25270546
38.

Factor structure of the Positive and Negative Syndrome Scale (PANSS) in Brazil: convergent validation of the Brazilian version.

Higuchi CH, Ortiz B, Berberian AA, Noto C, Cordeiro Q, Belangero SI, Pitta JC, Gadelha A, Bressan RA.

Braz J Psychiatry. 2014 Oct-Dec;36(4):336-9. doi: 10.1590/1516-4446-2013-1330. Epub 2014 Jul 16.

39.

What are the PANSS items most related with global improvements in patients with schizophrenia? Toward a reduced version of the PANSS.

Ortiz BB, Gadelha A, Higuchi CH, Pitta JC, Kagan S, Vong MR, Noto C, Hallak JE, Bressan RA.

Schizophr Res. 2014 Sep;158(1-3):277-8. doi: 10.1016/j.schres.2014.06.008. Epub 2014 Jul 5. No abstract available.

PMID:
25008793
40.

Evaluation of neurotransmitter receptor gene expression identifies GABA receptor changes: a follow-up study in antipsychotic-naïve patients with first-episode psychosis.

Ota VK, Noto C, Gadelha A, Santoro ML, Ortiz BB, Andrade EH, Tasso BC, Spindola LM, Silva PN, Abílio VC, Smith Mde A, Sato JR, Brietzke E, Cordeiro Q, Bressan RA, Belangero SI.

J Psychiatr Res. 2014 Sep;56:130-6. doi: 10.1016/j.jpsychires.2014.05.012. Epub 2014 Jun 4.

PMID:
24935901
41.

Fluvial transport potential of shed and root-bearing dinosaur teeth from the late Jurassic Morrison Formation.

Peterson JE, Coenen JJ, Noto CR.

PeerJ. 2014 Apr 10;2:e347. doi: 10.7717/peerj.347. eCollection 2014.

42.

Targeting the inflammatory pathway as a therapeutic tool for major depression.

Noto C, Rizzo LB, Mansur RB, McIntyre RS, Maes M, Brietzke E.

Neuroimmunomodulation. 2014;21(2-3):131-9. doi: 10.1159/000356549. Epub 2014 Feb 14. Review.

43.

PRODH polymorphisms, cortical volumes and thickness in schizophrenia.

Ota VK, Bellucco FT, Gadelha A, Santoro ML, Noto C, Christofolini DM, Assunção IB, Yamada KM, Ribeiro-dos-Santos AK, Santos S, Mari JJ, Smith MA, Melaragno MI, Bressan RA, Sato JR, Jackowski AP, Belangero SI.

PLoS One. 2014 Feb 3;9(2):e87686. doi: 10.1371/journal.pone.0087686. eCollection 2014.

44.

Tectal etiology for irrepressible saccades: a case study in a Rhesus monkey.

Gnadt JW, Noto CT, Kanwal JS.

Version 2. F1000Res. 2013 Mar 12 [revised 2013 Jan 1];2:85. doi: 10.12688/f1000research.2-85.v2. eCollection 2013.

45.

Neurotransmitter receptor and regulatory gene expression in peripheral blood of Brazilian drug-naïve first-episode psychosis patients before and after antipsychotic treatment.

Ota VK, Noto C, Gadelha A, Santoro ML, Silva PN, Melaragno MI, Smith Mde A, Cordeiro Q, Bressan RA, Belangero SI.

Psychiatry Res. 2013 Dec 30;210(3):1290-2. doi: 10.1016/j.psychres.2013.09.016. Epub 2013 Oct 7.

PMID:
24113126
46.

A pilot trial of intravenous pamidronate for chronic low back pain.

Pappagallo M, Breuer B, Lin HM, Moberly JB, Tai J, Noto C, Sanchez A, Manfredi PL.

Pain. 2014 Jan;155(1):108-17. doi: 10.1016/j.pain.2013.09.016. Epub 2013 Sep 21.

47.

Pharmacological and psychosocial management of mental, neurological and substance use disorders in low- and middle-income countries: issues and current strategies.

de Jesus Mari J, Tófoli LF, Noto C, Li LM, Diehl A, Claudino AM, Juruena MF.

Drugs. 2013 Sep;73(14):1549-68. doi: 10.1007/s40265-013-0113-4. Review.

PMID:
24000001
48.

Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia.

Asevedo E, Gadelha A, Noto C, Mansur RB, Zugman A, Belangero SI, Berberian AA, Scarpato BS, Leclerc E, Teixeira AL, Gama CS, Bressan RA, Brietzke E.

J Psychiatr Res. 2013 Oct;47(10):1376-82. doi: 10.1016/j.jpsychires.2013.05.032. Epub 2013 Jun 25.

PMID:
23806580
49.

Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia.

Noto C, Gadelha A, Belangero SI, Spindola LM, Rocha NP, de Miranda AS, Teixeira AL, Cardoso Smith MA, de Jesus Mari J, Bressan RA, Brietzke E.

J Psychiatr Res. 2013 Apr;47(4):467-71. doi: 10.1016/j.jpsychires.2012.12.010. Epub 2013 Jan 26.

PMID:
23360651
50.

Translation and adaptation of the Bipolar Prodrome Symptom Scale-Retrospective: Patient Version to Brazilian portuguese.

Pan PM, Jesus DR, Gadelha A, Bressan RA, Correll CU, Mansur RB, Zugman A, Noto C, Asevedo Ede M, Brietzke E.

Trends Psychiatry Psychother. 2013;35(1):62-75.

Supplemental Content

Support Center